The antimetabolite 3-bromopyruvate selectively inhibits Staphylococcus aureus

Antibiotic resistance is a serious public health problem at the global level. Available antibiotics have saved millions of lives, but are progressively losing their efficacy against many bacterial pathogens. While very few new antibiotics are being developed by the pharmaceutical industry, mainly due to the inherent low reward and high risk of antibiotic research, the rapid spread of antibiotic-resistant pathogens both in hospitals and in the community calls for new investments in antibacterial drug discovery.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research